Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$56.53M, compared with -$27.4M a year earlier.
Context
- Net debt amounted to 38.9% of total assets at the end of Q1 FY2026, down 54.9 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -106.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
Mixed currencies · from the balance sheet
- Latest · FY2025
- (80.26M) USD
- Year-over-year change
- -143.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (80.26M) | -143.0% |
| FY2024 | 2024-12-31 | (33.03M) | -274.2% |
| FY2023 | 2023-12-31 | (8.83M) | — |
| FY2022 | 2022-12-31 | (14.19M) | -24.5% |
| FY2021 | 2021-12-31 | (11.4M) | — |
Net Debt vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -106.3% is the 3rd highest of 8, against a peer median of -247.3%.
- Net debt amounts to 38.9% of total assets for EPRX.TO, versus a peer median of 11.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $214.88M USD | -0.8% | -9.8% | 39.1% | |
| Apr 2026 | -CA$2.48M CAD | -247.3% | — | 11.6% | |
| Mar 2026 | -$29.12M USD | -641.1% | -47.8% | 10.5% | |
| Mar 2026 | -$40.08M USD | -1105.6% | — | 55.9% | |
PRN.TOProfound Medical Corp. | Mar 2026 | -$42.86M USD | -3.2% | — | 58.3% |
| Mar 2026 | -CA$45.75M CAD | -1155.4% | — | 8.8% | |
| Mar 2026 | -$56.53M USD | -106.3% | — | 38.9% | |
| Mar 2026 | -CA$85.97M CAD | -136.6% | — | 7.7% | |
| Peer median (excluding EPRX.TO) | — | -247.3% | -28.8% | 11.6% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.89M | 24.74M | 19.2M | 33.1M | 80.42M |
| Short-term Investments | 9.01M | 0 | 0 | 0 | 0 |
| Net Receivables | 337.03K | 121.51K | 190.61K | 228.87K | 673K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 151.14K | 109 | 0 | 0 | (7.02K) |
| Total Current Assets | 30.6M | 25.18M | 19.8M | 34.44M | 84.94M |
| Property, Plant & Equipment (Net) | 589.07K | 695.48K | 452.97K | 424.92K | 985.33K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.37K | 3.37K | 6.85K | 80.76K | 64.22K |
| Total Non-current Assets | 620.44K | 698.85K | 459.82K | 505.68K | 1.05M |
| Total Assets | 31.22M | 25.88M | 20.12M | 34.94M | 85.99M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 74.44K | 107.53K | 10.37M | 71.82K | 78.31K |
| Tax Payables | 0 | 0 | 36.16K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 3.06K | 0 | 0 |
| Other Current Liabilities | 1.4M | 1.55M | 2.73M | (1.5M) | 1.43M |
| Total Current Liabilities | 2.27M | 4.14M | 19.23M | 4.46M | 5.62M |
| Long-term Debt | 9.26M | 10.3M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29.71K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.4M | 10.37M | 0 | 0 | 75.77K |
| Total Liabilities | 11.67M | 14.51M | 19.23M | 4.46M | 5.69M |
| Common Stock | 80.71M | 92.34M | 69.96M | 116.36M | 195.05M |
| Retained Earnings | (74.19M) | (97.45M) | (79.43M) | (131M) | (169.27M) |
| Accumulated OCI | 0 | 0 | (2.7M) | (5.98M) | (2.04M) |
| Other Stockholders Equity | 0 | 0 | 662.23K | 1.82M | 0 |
| Minority Interest | (833.84K) | (1.49M) | (1.32M) | (1.57M) | (1.59M) |
| Total Equity | 19.55M | 11.36M | 892.33K | 31.84M | 80.3M |
| Total Debt | 9.49M | 10.55M | 10.45M | 71.86K | 154.08K |
| Net Debt | (11.4M) | (14.19M) | (8.83M) | (33.03M) | (80.26M) |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.